Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sight Sciences, Inc. - Common Stock (NQ:SGHT)

4.720 +1.270 (+36.82%)
Streaming Delayed Price Updated: 3:30 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sight Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Scholastic, Matson, Digital World Acquisition And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big stocks recording gains in today’s session. Digital World Acquisition Corp. (NASDAQ: DWAC) climbed 69%... 
Via Benzinga
Sight Sciences' TearCare Surpasses Restasis Dry Eye Treatment, Trial Data shows
Sight Sciences Inc (NASDAQ: SGHT) released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis  
Via Benzinga
Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside... 
Via Benzinga
Analyst Expectations for Sight Sciences's Future
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 10, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023
 
Via Benzinga
BlackRock To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Keybanc raised the price target for BILL Holdings, Inc. (NYSE: BILL) from $110 to $140. Keybanc analyst Josh Beck maintained an Overweight rating. BILL Holdings shares fell 2.3% to $113.00 in... 
Via Benzinga
Recap: Sight Sciences Q1 Earnings
 
Via Benzinga
A Preview Of Sight Sciences's Earnings
 
Via Benzinga
Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
From Sight Sciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use
Sight Sciences Inc (NASDAQ: SGHT) published two-year results of the so-called "Romeo" study of the OMNI Surgical System. 
Via Benzinga
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical
From Sight Sciences, Inc.
Via GlobeNewswire
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract... 
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Clinical data includes long-term trial results and robust real-world comparative data from IRIS® Registry 
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team 
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures 
From Sight Sciences, Inc.
Via GlobeNewswire
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
From Sight Sciences, Inc.
Via GlobeNewswire
3 Prime Healthcare Takeover Targets
These three companies are attractive targets for their potential. 
Via The Motley Fool
Lions Gate Entertainment, DexCom, Yelp And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.